{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:05:40Z","timestamp":1791144340414,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1053\/j.gastro.2009.02.001","type":"journal-article","created":{"date-parts":[[2009,2,27]],"date-time":"2009-02-27T04:12:12Z","timestamp":1235707932000},"page":"1182-1197","source":"Crossref","is-referenced-by-count":299,"title":["Biological Therapies for Inflammatory Bowel Diseases"],"prefix":"10.1053","volume":"136","author":[{"given":"Paul","family":"Rutgeerts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Vermeire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Van Assche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2009.02.001_bib1","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","article-title":"Inflammatory bowel disease: clinical aspects and established and evolving therapies","volume":"12","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2009.02.001_bib2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/gut.35.3.360","article-title":"Frequency of glucocorticoid resistance and dependency in Crohn's disease","volume":"35","author":"Munkholm","year":"1994","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2009.02.001_bib4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0016-5085(99)70445-2","article-title":"Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease","volume":"117","author":"Sandborn","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/gut.2005.068809","article-title":"Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis","volume":"55","author":"Ardizzone","year":"2006","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2009.02.001_bib6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn's disease","volume":"332","author":"Feagan","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2009.02.001_bib7","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease","volume":"342","author":"Feagan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2009.02.001_bib8","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2009.02.001_bib9","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0016-5085(03)01214-9","article-title":"Randomized, double-blind comparison of 4 mg\/kg versus 2 mg\/kg intravenous cyclosporine in severe ulcerative colitis","volume":"125","author":"Van Assche","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib10","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.cgh.2006.04.001","article-title":"Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis","volume":"4","author":"Moskovitz","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2009.02.001_bib11","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib12","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.cgh.2006.04.022","article-title":"Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"4","author":"Rutgeerts","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2009.02.001_bib13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2009.02.001_bib14","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2009.02.001_bib15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib16","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2009.02.001_bib17","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2009.02.001_bib18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib19","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/j.gastro.2005.01.048","article-title":"Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease","volume":"128","author":"Lichtenstein","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib20","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib21","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.dld.2003.12.014","article-title":"Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease","volume":"36","author":"Borrelli","year":"2004","journal-title":"Dig Liver Dis"},{"key":"10.1053\/j.gastro.2009.02.001_bib22","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.cgh.2008.07.010","article-title":"Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study","volume":"6","author":"Thayu","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2009.02.001_bib23","doi-asserted-by":"crossref","DOI":"10.14309\/00000434-200809001-01117","article-title":"SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy","author":"Sandborn","year":"2008","journal-title":"Am J Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib24","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/j.gastro.2008.05.061","article-title":"A randomized, placebo-controlled study to evaluate the efficacy of infliximab in combination with methotrexate for the long-term treatment of Crohn's disease","volume":"135","author":"Feagan","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib25","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib26","article-title":"Long-term outcome of treatment with infliximab in 614 Crohn's disease patients: results from a single centre cohort","author":"Schnitzler","year":"2008","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2009.02.001_bib27","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2009.02.001_bib28","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study","volume":"128","author":"Jarnerot","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib29","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2009.02.001_bib30","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2009.02.001_bib31","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2009.02.001_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/j.1524-4733.2008.00335.x","article-title":"Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective","author":"Wu","year":"2008","journal-title":"Value Health"},{"key":"10.1053\/j.gastro.2009.02.001_bib33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib34","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2009.02.001_bib35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib36","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2009.02.001_bib37","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2009.02.001_bib38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2009.02.001_bib39","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2009.02.001_bib40","article-title":"Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study","author":"Fidder","year":"2008","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2009.02.001_bib41","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2009.02.001_bib42","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2009.02.001_bib43","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib44","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2009.02.001_bib45","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","article-title":"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy","volume":"354","author":"Yousry","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2009.02.001_bib46","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa042982","article-title":"Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin","volume":"352","author":"Feagan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2009.02.001_bib47","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.cgh.2008.06.007","article-title":"Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin","volume":"6","author":"Feagan","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2009.02.001_bib48","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa033402","article-title":"Anti-interleukin-12 antibody for active Crohn's disease","volume":"351","author":"Mannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2009.02.001_bib49","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate to severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib50","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gut.2005.079434","article-title":"A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease","volume":"55","author":"Reinisch","year":"2006","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2009.02.001_bib51","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/gut.2005.079392","article-title":"Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease","volume":"55","author":"Hommes","year":"2006","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2009.02.001_bib52","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1053\/j.gastro.2004.01.012","article-title":"A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease","volume":"126","author":"Ito","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib53","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1126\/science.289.5483.1352","article-title":"Treatment of murine colitis by Lactococcus lactis secreting interleukin-10","volume":"289","author":"Steidler","year":"2000","journal-title":"Science"},{"key":"10.1053\/j.gastro.2009.02.001_bib54","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.cgh.2006.03.028","article-title":"A phase 1 trial with transgenic bacteria expressing interleukin-10 in Crohn's disease","volume":"4","author":"Braat","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2009.02.001_bib55","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2036.2008.03778.x","article-title":"Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-1a in moderately active ulcerative colitis","volume":"28","author":"Pena-Rossi","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2009.02.001_bib56","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gut.40.3.320","article-title":"CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study","volume":"40","author":"Stronkhorst","year":"1997","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2009.02.001_bib57","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1053\/j.gastro.2007.08.035","article-title":"A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis","volume":"133","author":"Plevy","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib58","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2036.2005.02526.x","article-title":"Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease","volume":"22","author":"Kasran","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2009.02.001_bib59","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0002-9270(02)05907-5","article-title":"A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis","volume":"98","author":"Van Assche","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2009.02.001_bib60","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gut.2005.089854","article-title":"Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial","volume":"55","author":"Van Assche","year":"2006","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2009.02.001_bib61","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/j.1365-2036.2006.02904.x","article-title":"Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease","volume":"23","author":"Creed","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2009.02.001_bib62","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1056\/NEJMoa041109","article-title":"Sargramostim for active Crohn's disease","volume":"352","author":"Korzenik","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2009.02.001_bib63","unstructured":"Feagan BG, Anderson F, Radford-Smith GL, et al. Efficacy and safety of sargramostim in moderate to severe Crohn's disease: results of N.O.V.E.L 4, a phase III multicenter study. Gastroenterology 132(Suppl 2):A103"},{"key":"10.1053\/j.gastro.2009.02.001_bib64","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1046\/j.1365-2036.2003.01589.x","article-title":"Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial","volume":"17","author":"Sandborn","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2009.02.001_bib65","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1056\/NEJMoa013136","article-title":"Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis","volume":"349","author":"Sinha","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2009.02.001_bib66","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1056\/NEJM200006013422203","article-title":"A preliminary study of growth hormone therapy for Crohn's disease","volume":"342","author":"Slonim","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2009.02.001_bib67","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/gast.2002.30770","article-title":"Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease","volume":"122","author":"Hommes","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib68","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cgh.2005.11.013","article-title":"Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"4","author":"Schreiber","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2009.02.001_bib69","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/01.MIB.0000172807.26748.16","article-title":"RDP58 is a novel and potentially effective oral therapy for ulcerative colitis","volume":"11","author":"Travis","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2009.02.001_bib70","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1053\/j.gastro.2007.12.012","article-title":"Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial","volume":"134","author":"Lewis","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib71","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/01.ibd.0000225337.14356.31","article-title":"A phase 1\/2A trial of STA 5326, an oral interleukin-12\/23 inhibitor, in patients with active moderate to severe Crohn's disease","volume":"12","author":"Burakoff","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2009.02.001_bib72","first-page":"OP-G-93","article-title":"CCX282-B, an orally active inhibitor of chemokine receptor CCR9, in a randomized, double-blind, placebo-controlled phase 2 study in moderate to severe Crohn's disease","volume":"A22","author":"Keshav","year":"2006","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2009.02.001_bib73","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","article-title":"Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease","volume":"44","author":"Mackey","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1053\/j.gastro.2009.02.001_bib74","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1053\/j.gastro.2008.07.069","article-title":"Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study","volume":"135","author":"Feagan","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2009.02.001_bib75","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","article-title":"Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial","volume":"130","author":"Lemann","year":"2006","journal-title":"Gastroenterology"}],"updated-by":[{"DOI":"10.1053\/j.gastro.2009.04.007","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000}}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508509001772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508509001772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T01:45:53Z","timestamp":1589593553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508509001772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0016508509001772"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2009.02.001","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}